Neurocritical Care News

A pill containing antihypertensives and a statin, with or without aspirin, was associated with reduced functional decline, but not reduced cognitive decline, in those aged 65 years and older, researchers reported in JAMA Neurology.

Researchers recently found that the pharmacokinetic properties of vesicular monoamine transporter 2 inhibitors may play a role in the treatment of tardive dyskinesia.

Marriage was associated with a lower risk for dementia and mild cognitive impairment in later life, researchers reported in the Journal of Aging and Health.

Reduced kidney function was associated with increased levels of dementia-related blood biomarkers, but not an increased risk for Alzheimer’s disease or dementia, researchers reported in JAMA Network Open.

A web-based system for the diagnosis and treatment of recurrent benign paroxysmal positional vertigo was shown to be effective, researchers reported in JAMA Neurology.

PB006, the first biosimilar for natalizumab, showed comparable safety, efficacy and immunogenicity to the reference monoclonal antibody therapy in patients with relapsing-remitting MS, researchers wrote in JAMA Neurology.

Head injury was associated with decreased long-term survival time in a community-based cohort with more than 30 years of follow-up, researchers wrote in JAMA Neurology.

Neurogene Inc. announced the FDA has granted clearance to its investigational new drug application for NGN-401, an adeno-associated virus gene therapy candidate for treating Rett syndrome in female pediatric patients.

Individuals with mental disorders who attempted suicide were reported to have impaired or abnormal social decision-making, evidenced by neuro-electrophysiological activity, according to a study published in BMC Psychiatry.

The FDA issued a complete response letter on the accelerated approval of donanemab for treatment of early symptomatic Alzheimer’s disease, citing the limited number of patients with longer drug exposure data.